Literature DB >> 8417881

Substance abuse-related admissions to adult intensive care.

W A Baldwin1, B A Rosenfeld, M J Breslow, T G Buchman, C S Deutschman, R D Moore.   

Abstract

The frequency of adult surgical and medical intensive care unit (ICU) admissions related to substance abuse was determined at a large community, trauma, and tertiary referral hospital. Of 435 ICU admissions, 14 percent (95 percent confidence interval [CI], 5 to 23 percent) were tobacco related generating 16 percent of costs, 9 percent (95 percent CI, 0 to 18 percent) were alcohol related generating 13 percent of costs, and 5 percent (95 percent CI, 0 to 14 percent) were illicit drug related generating 10 percent of costs. In all, 28 percent (95 percent CI, 20 to 36 percent) of ICU admissions generating 39 percent of costs were substance abuse related. Substance abuse-related admissions were significantly longer and more costly than admissions not related to substance abuse (4.2 days vs 2.8 days, p = 0.004; $9,610 vs $5,890, p = 0.001). Frequency of substance abuse-related admission was linked with the patient's insurance status (Medicare, private insurance, uninsured). In the uninsured group, 44 percent of admissions were substance abuse related (95 percent CI, 35 to 52 percent), significantly higher than in the private insurance and Medicare groups, and generating 61 percent of all ICU costs in the uninsured group. Large fractions of adult ICU admissions and costs are substance abuse related, particularly in uninsured patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417881     DOI: 10.1378/chest.103.1.21

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

Review 1.  Alcohol-use disorders in the critically ill patient.

Authors:  Marjolein de Wit; Drew G Jones; Curtis N Sessler; Marya D Zilberberg; Michael F Weaver
Journal:  Chest       Date:  2010-10       Impact factor: 9.410

Review 2.  Street drug abuse leading to critical illness.

Authors:  Babak Mokhlesi; Prasad S Garimella; Aaron Joffe; Valerie Velho
Journal:  Intensive Care Med       Date:  2004-03-04       Impact factor: 17.440

3.  Substance dependence and psychiatric disorders are related to outcomes in a mixed ICU population.

Authors:  Mary R Suchyta; Callie J Beck; Colin W Key; Al Jephson; Ramona O Hopkins
Journal:  Intensive Care Med       Date:  2008-09-18       Impact factor: 17.440

4.  Psychiatric disorders and the ICU: gaps and opportunities.

Authors:  Christoph Pechlaner; Bruno Mégarbane; W Wolfgang Fleischhacker
Journal:  Intensive Care Med       Date:  2008-09-18       Impact factor: 17.440

Review 5.  Respiratory toxicities from stimulant use.

Authors:  T E Albertson; W F Walby
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

6.  Protandim does not influence alveolar epithelial permeability or intrapulmonary oxidative stress in human subjects with alcohol use disorders.

Authors:  Ellen L Burnham; Joe M McCord; Swapan Bose; Lou Ann S Brown; Robert House; Marc Moss; Jeanette Gaydos
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-20       Impact factor: 5.464

7.  Estimating the costs of substance abuse to the Medicaid hospital care program.

Authors:  K Fox; J C Merrill; H H Chang; J A Califano
Journal:  Am J Public Health       Date:  1995-01       Impact factor: 9.308

8.  The use of VV-ECMO in patients with drug dependencies.

Authors:  George Stoyle; Peter Fawcett; Ignacio Malagon
Journal:  J Artif Organs       Date:  2018-02-20       Impact factor: 1.731

Review 9.  Stimulants and the lung : review of literature.

Authors:  Will Tseng; Mark E Sutter; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

10.  The management of the poisoned patient using a novel emergency department-based resuscitation and critical care unit (ResCCU).

Authors:  Anita Mudan; Jennifer S Love; John C Greenwood; Carolyn Stickley; Victoria L Zhou; Frances S Shofer; David H Jang
Journal:  Am J Emerg Med       Date:  2020-06-28       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.